Drugs Policy

Debate between Crispin Blunt and Paul Flynn

Tuesday 18th July 2017 Commons Chamber

[Crispin Blunt]

It has not failed. If we adjust one part of the system and move from a categorisation of B to C, as we did with cannabis, then that sends a message about usage and the rest. However, if the supply of cannabis is in the hands of people who are not going to tell people what is in it, or educate them as to the effect it is going to have on their mind, it is hardly surprising that we see a massive increase in schizophrenia caused by the use of these drugs, because people do not know what they are buying and we are not in a position to educate them properly about the consequences of their use. That is why there is a public health issue about getting a regulated supply into place whereby we could educate people at the point of purchase. I will come on to talk about the relationship between the dealer and his interest in how he deals with his client base in a regulated and licensed system.

[Paul Flynn]

Having been in the House at the time of David Blunkett’s change in the category of cannabis, and very much involved with it, I remember that everyone predicted an increase in cannabis use when the classification was changed. That did not happen. In fact, there was a reduction in the use of cannabis when the penalties were less. Contrary to all the expectations, and the great argument we hear in this place, it is not the drugs that are killing people—it is prohibition that is killing people.

[Crispin Blunt]

While I am obviously minded to agree with the hon. Gentleman, the arguments that my hon. Friend the Member for Louth and Horncastle (Victoria Atkins) and the Government are putting forward in trying to send a message should be considered somewhere so that we can go through the evidence. That is very difficult to do in a charged environment where the tabloid press will be seeking to send a message if we are perceived to be weak in this area of public policy. Yet hundreds of thousands of people across the world are dying because this policy is in the wrong place globally. I rather hope that a royal commission here in the United Kingdom could assist us in getting to a place where, based on evidence, we can begin to lead the international debate.

As well as the decriminalisation of personal possession, we ought to consider the merits of a legal, regulated market taken out of the control of organised crime. A recent report by the drugs policy think-tank Volteface makes the case for a legal, regulated cannabis market in the UK to improve support, guidance and access to treatment for people experiencing problematic cannabis use. It found that the current illegal and unregulated market means that cannabis users are hidden from health practitioners, leaving them

“fumbling around in the dark trying to find them”.

Among people showing signs of cannabis dependence, only 14.6% have ever received treatment, help or support specifically because of their drug use, and 5.5% had received it in the previous six months. The report says a regulated market would provide

“opportunities for more public guidance, packaging controls, products which vary in potency, research into cannabis culture and consumption to improve interventions, and reduced stigma to enable access to services.”

I am sorry to say that the drug dealers reading the strategy and watching this debate will simply laugh at us. We are doing nothing to undermine their basic business model. By ensuring that supply is criminal, we have created a highly lucrative, criminal black market for the distribution and sale of drugs, worth an estimated £4.6 billion per year in the United Kingdom—and the UN Office on Drugs and Crime and Europol estimate that the global market is worth $435 billion a year. That is an astonishing amount of money, and it is hardly surprising that people arm themselves, and fight and kill, to try to maintain their share of that market.

Drugs are believed to account for some 20% of all crime proceeds, with about 50% of all organised crime groups believed to be involved in drugs, and about half of transnational organised crime proceeds derive from the drugs trade. Profit margins are enormous, with 100-fold increases in price from production to retail. Exploited customers, trapped in addiction—indeed, having been encouraged and incentivised there by the criminal dealer—turn to crime to pay the inflated prices. Those using heroin, cocaine or crack cocaine are estimated to commit between a third and a half of all acquisitive crime. Drug dealers vie with one another to gain market exclusivity in their domains, leading to further appalling gang violence.

Yet that is only part of the story, as the uncomfortable truth is that respect for our laws is diminished when large swathes of the population can see no difference between their recreational drugs of choice and their recreational use of alcohol and tobacco. Alcohol prohibition was an acknowledged public policy disaster when it was tried in the United States in the 1920s. If the state or its licensed agents became a benign, regulated monopoly supplier instead, that would smash the drug dealer’s business model. Proceeds from sales or taxation of sales would pay for treatment and public health education. We would protect people because they would know what they were buying.

Instead of more of the same, we should be brave enough to be at the forefront of international thinking. Legalisation, licensing and regulation may be radical ideas for the United Kingdom, but forms of decriminalisation are already being widely put into practice in Europe and in North America and Latin America. The merits of other countries’ approaches, and the extensive work of the Global Commission on Drug Policy, warrant proper consideration in British public debate and policy making. A royal commission would be able to do that. It would be the most appropriate way to consider fully and carefully the complex issues involved and all the policy options, exploring best practice abroad and responding to increasing calls here and internationally for a truly new strategy.